

Pharmacists' Contributions to the Management of Mental Health Conditions: A Comprehensive Review

Lin Feng¹, Gao Wei^{1*}, Zhao Lei¹

¹School of Pharmacy, Zhejiang University, Hangzhou, China.

*E-mail ✉ gao.wei@gmail.com

Received: 14 April 2024; Revised: 18 August 2024; Accepted: 18 August 2024

ABSTRACT

Pharmacists play a crucial role in the management and care of individuals with mental health disorders as key members of interdisciplinary healthcare teams. Their responsibilities go far beyond medication dispensing, encompassing patient counseling, adherence promotion, monitoring for drug interactions, evaluating therapeutic outcomes, and assisting in symptom control—while maintaining compassion and patient confidentiality. However, they encounter obstacles such as poor adherence, communication difficulties, and the persistence of social stigma. Pharmacists also navigate complex medication interactions, particularly those involving psychiatric drugs and dietary supplements. Within hospital settings, clinical pharmacists contribute by optimizing pharmacotherapy, tracking treatment responses, and providing education on psychotropic medication management. This review underscores the importance of advanced, targeted training programs to strengthen pharmacists' competencies in mental health care. Countries like the United States, the United Kingdom, and Australia have already established such initiatives, whereas Bulgaria is currently integrating mental health services into pharmacy practice, thereby broadening pharmacists' roles and enhancing public understanding. Collectively, these developments demonstrate the indispensable impact of pharmacists in advancing mental health outcomes and overcoming existing barriers.

Keywords: Substance use disorders, Depression, Interdisciplinary collaboration, Psychotropic drug interactions, Pharmaceutical counseling, Patient adherence

How to Cite This Article: Feng L, Wei G, Lei Z. Pharmacists' Contributions to the Management of Mental Health Conditions: A Comprehensive Review. *Ann Pharm Pract Pharmacother*. 2024;4:125-39. <https://doi.org/10.51847/ReKLpACV6c>

Introduction

Pharmacists play a pivotal role in the management of patients with mental health disorders, with responsibilities that extend far beyond the mere dispensing of medicines. Mental disorders encompass a broad spectrum of conditions affecting emotion, cognition, behavior, and perception, including affective and anxiety disorders, psychotic and eating disorders, obsessive-compulsive and cognitive impairments, as well as substance use and trauma-related conditions. Pharmacists are instrumental in ensuring the safe and effective pharmacological treatment of mental health problems such as depression, anxiety, bipolar disorder, and schizophrenia [1-4]. Their professional duties include conducting comprehensive medication reviews, resolving drug-related issues, managing polypharmacy, and monitoring for adverse effects [5-7].

Owing to their accessibility, pharmacists often act as the first point of contact for individuals experiencing mental health crises, particularly in settings where psychiatric services are limited. Upon recognizing concerning symptoms, they are expected to offer immediate guidance, initiate referrals to medical professionals, or activate emergency support systems [2]. Training in psychological first aid (PFA), de-escalation strategies, and ethical practice is therefore essential to prepare pharmacists for such critical interactions.

Enhancing motivation and psychological encouragement is vital for improving adherence to therapy. To achieve this, pharmacists utilize motivational interviewing techniques that require specialized instruction. This patient-centered method fosters trust and empowers individuals to actively engage in their treatment decisions. Ethical

responsibility and confidentiality are equally significant in mental health care, as patients tend to be highly protective of their personal and health information. Hence, pharmacists must conduct consultations in private, respectful environments that uphold confidentiality. Moreover, stigma, mistrust, and occasional hostility toward healthcare providers remain major obstacles [8]. Many individuals with mental illness face discrimination and shame, which can hinder their openness with pharmacists and compromise adherence to treatment.

Pharmacists must also be capable of detecting early warning signs of mental health decline—such as social isolation, mood instability, confusion, or hopelessness. This requires not only sound psychiatric knowledge but also refined communication skills to assess the need for medical attention accurately [9].

The aim of this study is to explore the multifaceted role of pharmacists in the care and management of individuals with mental disorders, emphasizing the principles of pharmaceutical care, effective patient communication, and multidisciplinary collaboration.

Materials and Methods

This narrative review compiles research published from 2000 onward, focusing on the evolving role of pharmacists in the management of mental disorders within interdisciplinary healthcare teams. The 1997 World Health Organization document outlining pharmacists' key professional roles—communication, education and training, care delivery, decision-making, leadership, and lifelong learning—served as the foundation for determining this timeline. A comprehensive literature search was conducted across databases such as PubMed, Web of Science, ScienceDirect, Scopus, and Google Scholar using keyword combinations that included “pharmacist,” “clinical pharmacist,” “mental disorders,” “depression,” “psychiatric conditions,” “substance abuse,” “mental health promotion,” “patient communication,” “psychotropic drug interactions,” “therapy adherence,” “counseling,” and “symptom management.” Reference lists of selected papers were also manually screened for additional relevant studies.

Studies that did not explicitly address the pharmacist's involvement in mental health management were excluded. The search produced a substantial number of articles, which were then reviewed and analyzed based on their relevance to the central themes of this review.

Results and Discussion

Main aspects

Key components of the pharmacist's role include patient counseling, educational support, promoting adherence, identifying and managing drug interactions, monitoring therapeutic efficacy, providing symptom relief, and ensuring confidentiality and empathy.

Counseling and education

Pharmacists provide in-depth counseling aimed at reinforcing treatment adherence and educating patients about their medications, potential side effects, and the overall importance of following prescribed regimens [3, 5, 10]. Furthermore, they tailor educational interventions to meet individual patient needs, which significantly enhances therapeutic outcomes [6, 11]. As integral members of multidisciplinary healthcare teams, pharmacists participate in case discussions, coordinate drug therapy plans, and contribute to personalized care strategies [2, 12]. Their collaboration with physicians and mental health professionals is essential to ensure a holistic approach to patient care.

Support for medication adherence

One of the key challenges in managing mental health conditions is ensuring that patients consistently take their prescribed medications. Pharmacists play an essential part in reinforcing the importance of adherence to treatment regimens and motivating patients, particularly when therapeutic benefits are not immediately noticeable. They also provide guidance on practical adherence strategies, such as using reminder tools and establishing structured routines for medication intake. A 2023 scoping review demonstrated that pharmacist-led interventions—encompassing educational programs, reminder systems, and ongoing follow-up—significantly improved medication adherence among individuals with mental health conditions in community, hospital, and multidisciplinary care settings [13].

Detection and management of drug interactions

Pharmacists possess the expertise to identify and manage potential drug interactions, particularly those involving psychiatric drugs used concurrently with other treatments. For example, certain antidepressants may interfere with cardiovascular agents or analgesics, necessitating dose adjustments or closer patient monitoring. Through comprehensive medication reviews and patient counseling, pharmacists play a pivotal role in minimizing the risks associated with polypharmacy in psychiatric care [14].

Therapeutic outcome monitoring

Pharmacists contribute substantially to evaluating the effectiveness and safety of treatment regimens. They help patients recognize both desired and adverse effects of medications, supporting the achievement of optimal therapeutic results. Moreover, pharmacists may suggest that patients consult their physicians to modify doses or switch medications if treatment goals are unmet or significant side effects arise [6].

Assistance with symptom management

Pharmacists are well-positioned to recommend supportive measures for managing symptoms of mental health disorders and mitigating medication-related adverse effects. This may include advising on dietary supplements or lifestyle interventions that enhance patient well-being. As accessible healthcare professionals, pharmacists often serve as the first point of contact, facilitating early recognition of psychological issues and directing individuals to appropriate healthcare services for timely management [10, 11].

Confidentiality and empathetic engagement

Maintaining patient confidentiality and fostering a supportive, stigma-free environment are vital responsibilities of pharmacists. By creating a trusting space, patients are encouraged to discuss their experiences and challenges openly. Nonetheless, pharmacists may encounter barriers such as persistent stigma surrounding mental illness, insufficient mental health training, and competing professional demands [2, 3, 11].

The principal responsibilities assumed by pharmacists in the care of patients with mental health conditions are illustrated in **Figure 1**.




Figure 1. The role of pharmacists in mental health support.

Support for medication adherence

Ensuring consistent adherence to prescribed pharmacotherapy in mental health care remains a major challenge for pharmacists. Their duties go far beyond simply dispensing medications—they also serve as key advocates for adherence by helping patients understand the therapeutic importance and expected benefits of their prescribed regimens [13, 15]. Effective adherence support strategies include building patient trust, maintaining transparent communication, explaining both the positive outcomes and potential adverse effects of medications, developing structured reminder systems and daily routines, monitoring progress, and arranging ongoing follow-up sessions [15, 16].

Motivational interviewing

Establishing a relationship of trust between pharmacists and patients is fundamental to achieving open, honest dialogue. By demonstrating empathy, neutrality, and active listening, pharmacists create a safe setting where patients can openly discuss difficulties such as medication side effects, social stigma, or waning motivation that may hinder adherence. A particularly valuable counseling approach is motivational interviewing, which empowers patients to actively participate in their treatment planning. Through this collaborative method, pharmacists help patients explore their personal motivations for improvement, identify internal barriers, and make informed decisions about continuing therapy.

Regular consultation

Pharmacists are central to educating patients about the therapeutic value and potential risks of their medications, emphasizing that consistent use of prescribed treatments can markedly improve mental health symptoms and overall well-being. They also warn against the consequences of inconsistent or abrupt discontinuation of medication, which can worsen clinical outcomes. When side effects arise, pharmacists can offer advice on symptom relief and, if needed, coordinate with physicians for dose or drug modifications. Such continuous engagement not only alleviates patients' concerns but also strengthens their commitment to therapy. Regular pharmacist-patient consultations—whether spontaneous discussions during medication collection or structured appointments scheduled similarly to medical visits—represent a cornerstone of contemporary pharmacy practice. These interactions improve adherence, minimize medication errors, reduce hospital admissions, and enhance quality of life [15]. With advancing technology, remote pharmaceutical consultations through phone or video calls are gaining traction as effective alternatives, particularly for patients in underserved or rural regions. Systematic reviews have demonstrated that such digital interventions substantially enhance treatment adherence and clinical outcomes in chronic and mental health conditions.

Reminders

Pharmacists play a pivotal role in helping patients manage their medication routines through reminder tools and structured dosing schedules [17, 18]. They often recommend the use of smartphone apps, calendar alerts, or pill organizers and may encourage family participation to reinforce medication-taking behavior. Consistent follow-up assessments by pharmacists further ensure that patients remain engaged and informed about their treatment progress. This sustained, personalized involvement strengthens adherence and fosters a deeper understanding of therapeutic goals. Moreover, the integration of digital health solutions into pharmaceutical care has demonstrated notable success in improving medication adherence among individuals with mental health disorders by enhancing accessibility, continuity, and the overall quality of support services [19, 20].

Detection and management of interactions between psychiatric medications, other drugs, and dietary supplements

This area represents a critical element of the pharmacist's professional responsibilities. Pharmacists employ a range of preventive and monitoring strategies to minimize adverse outcomes and ensure patient safety [21]. To accurately identify and assess potential drug interactions, they rely on specialized clinical resources and databases such as Lexicomp, Micromedex, and UpToDate, which provide detailed data regarding interaction mechanisms, clinical relevance, and appropriate management strategies [22]. In addition to evaluating prescribed medications and dosages, pharmacists take into account patient-specific variables—such as age, body weight, comorbidities, and lifestyle habits—to reduce the risk of harmful interactions. This assessment is particularly important in psychiatric populations, where polypharmacy and unsupervised supplement use are common. Pharmacists remain alert for clinical warning signs of interactions, including mood instability, sedation, dizziness, or gastrointestinal symptoms [23]. Evidence from a 2022 study highlights that pharmacists play a crucial role in uncovering clinically

significant interactions often missed during routine medical reviews. Their integration into multidisciplinary healthcare teams enhances pharmacotherapy safety and decreases the incidence of adverse drug reactions among psychiatric patients [24].

Consultations regarding supplement use

Pharmacists frequently advise patients on the concurrent use of dietary supplements and herbal products—such as St. John's wort, omega-3 fatty acids, vitamins, and minerals—that may influence psychiatric drug efficacy or safety. St. John's wort (*Hypericum perforatum*), for example, is known to activate cytochrome P450 enzymes, particularly CYP3A4, thereby reducing the plasma concentration of many psychotropic medications. When used alongside serotonergic antidepressants, it can also precipitate serotonin syndrome [25]. Pharmacists emphasize the importance of consulting healthcare professionals before initiating any new supplement or over-the-counter medication to prevent such adverse outcomes. Several herbal and dietary substances can either induce or inhibit hepatic enzymes vital to drug metabolism. Inducers—such as St. John's wort, broccoli, Brussels sprouts, cauliflower, caffeine, and essential oils from rosemary or garlic—can decrease drug bioavailability and weaken therapeutic effects [25]. Conversely, inhibitors like ginkgo biloba, red grapefruit, valerian, hops, and milk thistle may elevate drug concentrations, increasing the risk of toxicity [26].

Consultations on interactions with other pharmaceuticals, including psychotropic agents

A broad spectrum of clinically important drug interactions occurs at both pharmacokinetic and pharmacodynamic levels [27]. Medications such as lithium salts possess a narrow therapeutic window, necessitating vigilant monitoring. Traditional neuroleptics and tricyclic antidepressants are also associated with significant risks—neuroleptics due to their diverse receptor activity and tricyclics because of their cardiotoxic potential in overdose situations, which poses a serious concern in patients at risk for self-harm. Although newer generations of antipsychotic agents have improved therapeutic profiles, they can still interact with other psychotropic or somatic medications through metabolic pathways. Most pharmacokinetic interactions involving these modern antipsychotics stem from altered activity of key metabolic enzymes, particularly cytochrome P450 (CYP) monooxygenases and uridine diphosphate-glucuronosyltransferases (UGTs), which are essential for drug biotransformation [14]. Likewise, selective serotonin reuptake inhibitors (SSRIs), widely prescribed for depression and anxiety, may lead to serotonin syndrome if combined inappropriately with certain drugs, supplements, or even foods, and their use in younger patients may heighten suicide risk. Furthermore, alcohol consumption can modify drug metabolism—chronic use induces metabolizing enzymes and diminishes drug efficacy, whereas acute intake inhibits metabolism, potentially intensifying drug effects or toxicity.

Methodological approach for counseling on the concurrent use of multiple medications

- Information gathering and assessment of herbal product consumption. Pharmacists conduct a thorough review of patients' use of herbal and complementary products such as St. John's wort, valerian, ginkgo biloba, ginger, garlic, and melatonin. They document the type, dosage, frequency, and concurrent use with prescribed medications to identify potential risks of interaction. This evaluation forms the foundation for determining the likelihood and severity of drug-herb interactions.
- Identification of potential interactions and associated risks. Many herbal preparations can alter the efficacy or safety of psychotropic agents, including antidepressants and antipsychotics. St. John's wort, commonly used to alleviate depressive symptoms, may interact with these drugs and elevate the risk of serotonin syndrome. Using specialized drug-interaction databases, pharmacists identify such risks and communicate appropriate warnings to patients. Similarly, valerian, often taken for anxiety or insomnia, may potentiate the effects of sedative-hypnotics, while melatonin—used to manage sleep disorders—requires careful monitoring when administered with antidepressants or antipsychotics.
- Patient education and awareness. Pharmacists play a pivotal role in explaining how herbal remedies exert their effects, their limitations, and the potential risks associated with their use. They stress that “natural” does not equate to “risk-free,” particularly for individuals managing chronic illnesses or taking multiple medications. Pharmacists encourage patients to follow recommended dosing practices, start with minimal effective doses, and remain vigilant for side effects, maintaining ongoing communication with their pharmacist throughout treatment.
- Promoting open communication. To build trust and obtain complete information about all products a patient may be taking, pharmacists emphasize the importance of honesty and transparency. Some patients may

conceal their use of herbal or alternative therapies, requiring reassurance that the pharmacist's objective is to support safe and effective treatment rather than to criticize their choices.

- Continuous monitoring. Pharmacists should urge patients to attend regular follow-ups and report any health changes or outcomes from using alternative products. This enables continuous evaluation of the effectiveness and safety of combined therapies, allowing for timely adjustments when necessary.

Challenges faced by pharmacists when communicating with patients with mental health disorders

Pharmacists often experience considerable difficulties when engaging with patients affected by psychiatric conditions. Effective communication in such contexts demands empathy, patience, and an understanding of the distinct psychological and cognitive barriers these patients may face.

Difficulties in understanding and communication

Certain psychiatric disorders, including schizophrenia and bipolar disorder, are frequently associated with cognitive dysfunctions that impede patients' ability to grasp complex medication-related information, such as correct dosing, potential adverse effects, and possible interactions [28]. These barriers make counseling particularly challenging and underscore the importance of individualized communication strategies. Pharmacists should use clear, simplified language, repeat key points, and apply verification methods such as the "teach-back" approach to ensure comprehension [9]. Combining verbal explanations with visual materials can further assist patients with cognitive limitations in adhering to their treatment regimens [29]. Adopting this structured, patient-centered communication style not only improves adherence but also reduces the likelihood of medication errors.

Nonadherence and reduced motivation

Medication noncompliance remains a widespread issue among psychiatric patients, often resulting from side effects, skepticism about treatment efficacy, lack of motivation, or cognitive impairments leading to forgetfulness [30]. These challenges can severely compromise long-term treatment success. Pharmacists play an instrumental role in addressing this problem by fostering trust, closely monitoring adherence, and tailoring interventions to individual needs. Practical solutions may include digital reminder tools, compartmentalized dosing organizers, structured medication schedules, and motivational interviewing to strengthen internal motivation [16]. Additionally, consistent education and open discussions about the benefits of pharmacotherapy and realistic treatment goals can significantly improve patient engagement and adherence [15].

Limited communication skills during crises and reduced concentration

During acute mental health episodes or periods of symptom exacerbation, patients with psychiatric conditions may experience heightened anxiety, irritability, aggression, or emotional instability, all of which can complicate effective communication with healthcare providers, including pharmacists. Consequently, pharmacists must cultivate specialized crisis communication skills such as maintaining patience, practicing active listening, demonstrating emotional control, and showing empathy. Effective de-escalation relies on employing a calm and reassuring tone, maintaining open and non-threatening body language, and avoiding confrontational or judgmental statements [31]. Additionally, creating a safe, structured environment and providing clear, consistent instructions can foster a sense of trust and cooperation, even in acute or high-stress situations.

The pharmacist's role in community consultation and public education on mental health

Pharmacists hold a pivotal position in advancing public knowledge and awareness of mental health issues. Beyond offering individualized counseling to patients, they increasingly participate in preventive and educational programs that aim to counteract stigma and encourage open discourse about mental well-being [32]. According to the World Health Organization (WHO) and the International Pharmaceutical Federation (FIP), the role of the modern pharmacist extends far beyond the traditional function of medication dispensing. The WHO/PHARM/97/599 framework outlines key professional duties, including effective communication, patient education, the provision of care, evidence-based decision-making, leadership, and lifelong learning [33]. These principles support the active engagement of pharmacists within their communities, particularly in promoting mental health literacy and educational outreach [34].

Key components of the pharmacist's contribution to public mental health education:

- Promoting mental health awareness. In nations such as the United States and Canada, pharmacists are actively involved in public health efforts to enhance mental health literacy. They participate in national and regional

awareness campaigns, use digital communication platforms, and provide information on managing stress, anxiety, and depression [35]. Through participation in mental health events and outreach activities, pharmacists help foster early recognition of symptoms and timely access to care.

- Educating on the safe use of psychotropic medications. Pharmacists offer essential guidance to patients and caregivers on the appropriate administration of psychotropic medications, including dosage schedules, treatment duration, possible interactions (e.g., with alcohol or tyramine-containing foods), and potential adverse effects. They emphasize that strict adherence to prescribed regimens is crucial for symptom stabilization and relapse prevention.
- Combating stigma and encouraging early treatment. Stigmatization often prevents individuals from seeking help for mental illnesses. In the United Kingdom, pharmacists play an active role in anti-stigma campaigns and educational programs that promote informed communication with affected individuals [36]. Through these initiatives, they help normalize discussions about mental health and reinforce the message that psychiatric conditions are manageable medical issues.
- Participation in preventive and health-promotion initiatives. Pharmacists contribute to public health programs that address mental health risk factors such as stress, sleep disturbances, and substance misuse. Their efforts include leading informational sessions and distributing educational materials that highlight strategies for improving emotional resilience and stress management.
- Referral and connection to specialized care. Pharmacists act as facilitators by guiding patients toward additional professional help, including referrals to psychiatrists, psychologists, and community mental health services. They also provide contact information for local support systems, including helplines and peer-support organizations.
- Involvement in digital and online education. Pharmacists are increasingly using digital platforms and social media to promote mental health awareness. Their activities include hosting webinars, disseminating e-newsletters, and developing online campaigns aimed at the general public. These initiatives help reach broader audiences and sustain engagement in mental health education.

In Bulgaria, the role of pharmacists in mental health promotion is gradually expanding. Various pharmacies and professional bodies are initiating educational projects and offering consultations to the public. The National Mental Health Policy (2004–2012) [37] issued by the Ministry of Health underscores the importance of intersectoral collaboration—including with the pharmaceutical profession—to strengthen community-based mental health support [37].

Suggested methodology for certain conditions

Approach for patients with depressive disorders

Pharmacists play a pivotal role in improving the overall quality of life and aiding the recovery journey of individuals suffering from depression [38]. Managing patients with depressive symptoms requires a comprehensive strategy that extends beyond the mere dispensing of medications, encompassing continuous guidance, monitoring, and emotional support throughout therapy.

- Providing instructions on proper antidepressant use. Pharmacists educate patients on the correct administration of their prescribed antidepressants, including dosage schedules, methods of intake, and expected therapeutic timelines. They explain that the effects of these drugs generally become evident after 2–4 weeks, helping patients remain motivated and adhere to the regimen during the early treatment period [16, 39].
- Explaining side effects and offering management strategies [40]. Common adverse effects such as drowsiness or sexual dysfunction often discourage patients from maintaining their medication regimen. Since sexual dysfunction remains a relatively underexplored issue that significantly contributes to therapy discontinuation [41–43], pharmacists should openly discuss these effects, propose coping strategies, and guide patients on when to seek medical intervention if the reactions become intolerable.
- Tracking progress and offering emotional support. During routine interactions, pharmacists can assess both physical and emotional aspects of a patient's condition. Encouraging open communication about any observed changes helps detect emerging issues early. They can also provide stress management techniques and, when necessary, refer patients to specialists such as psychiatrists or psychologists for additional care [44].

- Identifying and preventing potential drug interactions. Patients with depression frequently use multiple medications, increasing the risk of adverse interactions. Pharmacists evaluate potential conflicts—such as between monoamine oxidase inhibitors (MAOIs) and tyramine-rich foods—and counsel patients on substances or combinations to avoid [45].
- Promoting educational programs for depressive symptom management. Pharmacists can strengthen community health by organizing short educational sessions that focus on coping with depression and stress. These may include guidance on healthy lifestyle habits, exercise routines, proper nutrition, and maintaining consistent daily schedules. As emphasized by Bingham *et al.* (2019), pharmacist-led interventions can promote improved nutrition, physical activity, and sleep quality among individuals with mental health challenges [46].
- Detecting early signs of suicidal ideation. Given that patients with depression are especially at risk for suicide, particularly during the initial stages of treatment when increased energy precedes mood enhancement, pharmacists must remain alert to warning signs such as sudden mood shifts, hopeless statements, or behavioral changes [47]. Upon recognizing such indicators, immediate referral to emergency or specialized mental health services is essential.

Approach for individuals with dependence on psychoactive substances

Pharmacists play a crucial role in supporting individuals struggling with substance dependence, which requires a compassionate, empathetic, and nonjudgmental approach grounded in professional ethics. Their effectiveness relies on proficiency in motivational interviewing, brief interventions, and making timely referrals to specialized treatment programs. People with substance use disorders often face multifaceted challenges encompassing medical, psychological, and social dimensions, frequently compounded by stigma, co-occurring mental illnesses, and social exclusion.

In both community and hospital settings, pharmacists are well-positioned to deliver educational, therapeutic, and motivational guidance as part of a multidisciplinary framework of care. Their responsibilities include identifying high-risk behaviors, recommending medication-assisted treatment (MAT), and providing information on the safe and effective use of therapies such as naltrexone, methadone, and buprenorphine [48].

Key principles for counseling patients with substance addictions:

- Identifying signs of addiction. Warning indicators of potential substance misuse include repeated or premature requests for controlled medications like opioids or benzodiazepines, claims of lost prescriptions, or patterns of obtaining drugs from multiple prescribers or pharmacies (“doctor/pharmacy shopping”). Pharmacists must address such cases tactfully, ensuring discretion and refraining from assumptions or stigmatizing behavior [49].
- Providing education on safety and risk awareness. Pharmacists should clearly communicate the health hazards linked to prolonged or inappropriate use of psychoactive substances. Harm reduction strategies—such as adherence to prescribed doses and the avoidance of mixing medications with alcohol or illicit substances—are critical to minimizing risks [50].
- Encouraging cessation through motivational interviewing. By utilizing motivational interviewing techniques, pharmacists help patients recognize the extent of their dependence and encourage personal motivation toward recovery. Asking open-ended questions and facilitating reflective discussion about the effects of addiction can prompt self-awareness and readiness for change. Upholding privacy and adopting a nonjudgmental, empathetic attitude fosters trust and creates a supportive environment conducive to honest communication [51, 52].
- Assisting with maintenance pharmacotherapy. Pharmacists have an essential function in overseeing patients receiving maintenance medications for opioid or other substance addictions, such as methadone or buprenorphine. They ensure appropriate medication use, provide counseling on possible adverse effects, and monitor treatment adherence [53, 54].
- Facilitating referrals to specialized care and resources. Pharmacists can connect patients with addiction specialists, psychiatrists, counselors, or rehabilitation centers. They also guide individuals toward available hotlines, community-based resources, and support networks that provide professional counseling and assistance for substance use recovery [2].

The involvement of clinical pharmacists in hospital-based therapeutic management of individuals with mental health disorders

Clinical pharmacists occupy a vital position within multidisciplinary hospital teams dedicated to the treatment of patients with psychiatric conditions. Their in-depth expertise in pharmacotherapy ensures the rational, safe, and individualized administration of psychotropic medications in hospital mental health units. Through close collaboration with other healthcare professionals, clinical pharmacists significantly enhance treatment effectiveness, improve patient safety, and support adherence to prescribed psychiatric regimens [2].

Although the structure and implementation of clinical pharmacy services vary internationally, many healthcare systems now recognize the pharmacist as an indispensable member of inpatient mental health teams. Countries such as the United Kingdom, Canada, and Australia have long-established models where pharmacists in psychiatric units actively participate in tasks such as medication reconciliation, treatment optimization, and psychoeducational interventions [55].

In Bulgaria, the integration of clinical pharmacy practice is progressing gradually. National health initiatives are underway to expand the role of pharmacists in hospitals through the establishment of clinical positions and standardized protocols for collaborative care. These developments align with European directives aimed at strengthening the pharmacist's contribution to psychiatric practice and ensuring continuity of care for patients with complex therapeutic needs [56].

Key duties of clinical pharmacists in psychiatric care include:

- Evaluation of pharmacotherapy and interaction management. Within psychiatric settings, clinical pharmacists are responsible for critically reviewing medication regimens to identify potential drug-drug interactions, duplications, or contraindications. Special focus is given to the complex pharmacokinetic and pharmacodynamic characteristics of psychotropic drugs, especially in polypharmacy situations. Additionally, they assess potential interactions between psychotropic agents and non-psychiatric drugs or dietary supplements—such as St. John's wort, omega-3 fatty acids, or over-the-counter preparations—that may compromise therapeutic efficacy or safety [14].
- Design of individualized treatment approaches. Working collaboratively with psychiatrists, nurses, and other healthcare professionals, clinical pharmacists contribute to the development of tailored therapeutic strategies that consider the patient's diagnosis, clinical history, comorbidities, and prior treatment responses. Their role involves:
 - Adjusting dosages of psychotropic medications to achieve optimal therapeutic outcomes
 - Monitoring therapeutic serum concentrations of agents such as lithium and valproate
 - Managing cases of drug resistance or hypersensitivity
 - Minimizing adverse effects, including sedation, metabolic disturbances, or extrapyramidal reactions.

Their specialized expertise extends to therapeutic drug monitoring, pharmacogenomic evaluation, and the evidence-based selection of alternative pharmacologic options in cases presenting with treatment resistance or therapeutic complexity [55].

- Monitoring of therapeutic outcomes and patient progress. Clinical pharmacists play a central role in the continuous evaluation of hospitalized patients undergoing psychotropic therapy. Their responsibilities include documenting clinical improvements—such as mood stabilization, symptom reduction, or decreased agitation—and promptly identifying adverse reactions, toxicity, or suboptimal therapeutic responses. This ongoing surveillance enables rapid modification of treatment plans when necessary. Additionally, they supervise the safe discontinuation of medications by ensuring adherence to appropriate tapering strategies, thereby minimizing withdrawal phenomena and preventing relapse or rebound symptoms. Within hospital settings, their direct participation in multidisciplinary discussions facilitates timely therapeutic adjustments and ensures safer progression across treatment stages, including initiation, maintenance, and withdrawal [2].
- Patient and family education. Clinical pharmacists serve as accessible and knowledgeable sources of information for both patients and caregivers, providing practical, evidence-based counseling regarding the correct administration of psychotropic drugs. They emphasize the importance of consistent adherence, explain dosing regimens, and clarify concerns related to drug efficacy, potential adverse effects, and therapeutic expectations. Furthermore, they actively dispel misconceptions surrounding psychiatric pharmacotherapy and foster open communication, helping reduce stigma and encouraging sustained engagement in mental health treatment [9].
- Education and training of healthcare professionals. Beyond direct patient care, clinical pharmacists are key contributors to the ongoing education and competency development of healthcare teams. They provide

updates on advances in psychopharmacology, emerging pharmacogenomic applications, revised treatment guidelines, and strategies to minimize medication errors in psychiatric practice. Through lectures, workshops, case reviews, and the creation of standardized protocols, they enhance clinical decision-making and promote adherence to evidence-based standards. In several regions, including the United States, Australia, and parts of Europe, clinical pharmacists hold clearly defined educational roles within psychiatric institutions, where they are directly involved in guideline implementation and multidisciplinary training to improve overall treatment quality [12, 57, 58].

Figure 2 presents an overview of the clinical pharmacist's multifaceted responsibilities in the management of mental health disorders.




Figure 2. The role of clinical pharmacists in the hospital-based therapeutic care of patients with mental disorders.

In Bulgaria, the integration of clinical pharmacists into hospital-based healthcare remains an evolving process, supported by ongoing academic and institutional initiatives that aim to establish clinical pharmacy as a formal component of multidisciplinary medical practice [59]. Although the number of pharmacists specializing in psychiatric care is still relatively small, their involvement within hospital systems—particularly in tertiary and university hospitals—is progressively increasing.

Discussion and future perspectives

The growing complexity of mental health treatment underscores the urgent demand for dedicated educational programs tailored to pharmacists. Managing patients with psychiatric conditions requires not only individualized therapeutic approaches but also refined interpersonal and clinical communication skills that go beyond standard pharmaceutical training. The rationale for such advanced education lies in preparing pharmacists to deeply understand psychiatric disorders, psychopharmacology, and the nuances of mental health treatment while developing competencies in motivational interviewing, crisis communication, and comprehensive medication

management. Moreover, pharmacists must be adept at tackling prevalent issues in psychiatric care, including poor adherence, polypharmacy, and adverse drug effects.

Professional organizations, universities, and healthcare institutions can all play pivotal roles in implementing these specialized programs, which typically include modules on identifying psychiatric symptoms, enhancing communication with patients, and promoting adherence to treatment plans.

Several countries have already established structured pharmacist training initiatives in the field of mental health care:

- United States. The American Pharmacists Association (APhA) delivers programs such as Mental Health First Aid, which equip pharmacists to identify early behavioral warning signs, provide initial support, and refer patients to appropriate care. Furthermore, many U.S. universities have integrated psychiatric pharmacy tracks into their postgraduate curricula.
- United Kingdom. The Royal Pharmaceutical Society (RPS) has introduced the Mental Health Pharmacy Competency Framework, encompassing modules on therapeutic decision-making, patient communication, and clinical evaluation to strengthen pharmacists' ability to deliver safe, effective, and empathetic psychiatric care.
- Australia. The Pharmaceutical Society of Australia (PSA) offers advanced and practice-based training designed for pharmacists managing patients with conditions such as depression, anxiety, bipolar disorder, and schizophrenia. The curriculum focuses on therapeutic communication, psychological support, and crisis management skills.
- Canada. The Canadian Society of Hospital Pharmacists (CSHP) provides specialized training for pharmacists in hospital psychiatric units, emphasizing medication therapy management, symptom recognition, and individualized pharmacological strategies.
- Bulgaria. Although still developing, pharmacy education in Bulgaria is beginning to include modules on mental health communication. A notable example is the Psychopharmacology and Pharmacopsychiatry course offered at the Medical University of Plovdiv, which integrates instruction on interacting with patients experiencing mental illness into the Pharmacist Assistant training program [60]. This advancement reflects the growing acknowledgment of the importance of preparing pharmacists to engage effectively and compassionately with individuals facing mental health challenges.

Enhanced education and specialized training in psychiatric pharmacy have the potential to significantly improve the quality of pharmacist–patient interactions, fostering stronger therapeutic relationships that lead to better medication adherence, earlier recognition of relapses or complications, and a reduction in the stigma surrounding mental illness.

Pharmaceutical care is a patient-centered professional approach in which pharmacists assume responsibility for addressing a patient's medication-related needs and are held accountable for the outcomes of this care. Within the field of mental health, this approach extends beyond accurate dispensing and monitoring of psychotropic medications to encompass close collaboration with other healthcare providers to achieve therapeutic goals, mitigate adverse effects, and enhance patient well-being through consistent, individualized follow-up. Emerging care models that can strengthen pharmacists' roles include integrated mental health–pharmacy collaborative frameworks, the inclusion of pharmacists in primary care mental health teams, and the adoption of pharmacogenomic-based strategies for individualized therapy optimization.

Current research gaps emphasize the urgent need for standardized outcome measures to assess the effectiveness of pharmacists' interventions in mental health settings, an expansion of interventional studies across diverse clinical environments, and greater exploration of digital health technologies in psychiatric pharmaceutical care.

The major strengths of the present study lie in its extensive synthesis of global practices and clinical guidelines, its dual focus on hospital and community pharmacy services, and its integration of patient-centered communication principles. Nevertheless, certain limitations exist, such as the limited availability of empirical evidence from Bulgarian healthcare settings and the insufficient analysis of long-term therapeutic outcomes. Although existing recommendations establish an essential framework for pharmacist participation in mental health management, considerable research gaps remain. Most prior investigations have concentrated on pharmacotherapy optimization and adherence support, leaving a lack of evidence concerning the broader psychosocial and collaborative functions that pharmacists could assume within multidisciplinary mental health teams. Future research should therefore focus on innovative collaborative care models that unite pharmacists,

physicians, psychologists, and community stakeholders to address not only medication management but also patient education, destigmatization, and long-term rehabilitation outcomes.

Additionally, developing new frameworks that expand pharmacists' duties beyond traditional dispensing can further enhance their impact. Promising advancements include the integration of digital health technologies, interprofessional collaborative models, and structured mental health first aid training. Such systems could ensure the systematic inclusion of pharmacists within mental healthcare pathways, facilitating early identification of mental health issues, continuity of care, and timely crisis response.

In alignment with these goals, the supplementary materials of this study seek to address existing shortcomings by offering practical, evidence-based guidance: (i) a detailed, stepwise manual on pharmaceutical care with specific recommendations for the combined use of psychotropic agents in individuals with mental disorders, (ii) a structured framework for the pharmaceutical management of patients with depression, and (iii) a corresponding framework for managing patients with psychoactive substance use disorders. Collectively, these materials are intended to provide a foundation for the creation of standardized, evidence-driven tools that support pharmacists and multidisciplinary teams in delivering more coordinated, effective, and patient-focused mental health care.

Conclusion

Pharmacists are now widely acknowledged as integral members of mental healthcare teams, with responsibilities that extend far beyond traditional medication dispensing. Their contributions encompass educating and counseling patients, promoting adherence to prescribed regimens, detecting and managing drug interactions, tracking therapeutic effectiveness and adverse effects, and providing support during crises. Additionally, pharmacists play a vital role in reducing societal stigma and advancing mental health literacy within their communities.

Internationally, numerous healthcare systems have already implemented successful strategies to incorporate pharmacists into multidisciplinary mental health teams and to establish specialized training initiatives that strengthen their expertise in psychopharmacology, crisis management, and motivational communication. In Bulgaria, this professional role continues to evolve, supported by growing national efforts to introduce clear policies, collaborative protocols, and educational frameworks that will enable the consistent and effective delivery of pharmaceutical care in psychiatric practice.

Looking forward, priority should be given to developing standardized evaluation instruments that measure the outcomes of pharmacist-led interventions, adopting digital technologies to facilitate remote consultations, and designing integrated collaboration models involving physicians, psychologists, and social service professionals. These strategies will support early detection of symptom worsening, reduce risks associated with medication use, and foster stronger trust between patients and pharmacists.

Ultimately, pharmacists must be recognized not only as experts in pharmacotherapy but as active collaborators in the holistic treatment, rehabilitation, and long-term support of individuals with mental health disorders—an evolving partnership that is poised to play an increasingly pivotal role in modern healthcare systems.

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: None

References

1. Chen T. Community pharmacy's role in managing mental illness. *Aust J Pharm.* 2008;89(1058):74–6.
2. Rubio-Valera M, Chen TF, O'Reilly CL. New roles for pharmacists in community mental health care: a narrative review. *Int J Environ Res Public Health.* 2014;11(10):10967–90. doi:10.3390/ijerph111010967
3. Panesar K. Barriers to counseling patients with mental health disorders. *US Pharm.* 2016;41(11):30–3. Available from: <https://www.uspharmacist.com/article/barriers-to-counseling-patients-with-mental-health-disorders#:~:text=Health%20System->

- Related%20Factors%3A%20The,counseling%20and%20lack%20of%20time.&text=Other%20issues%20in clude%20the%20lack,of%20the%20patient%27s%20medical%20background. [Accessed 09.04.2025].
4. Karolewicz B, Nowak M, Gawin A, Milejski P, Owczarek A. Identification of the area services provided by a pharmacist in the care of patients with mental health problems: conditions, possibilities of care providing, and the needs of patients. *Acta Pol Pharm.* 2020;77(5):281–96. doi:10.32383/farmopol/125320
 5. Tai M, Vu L, Bostwick JR. Antidepressant treatment concerns and recommendations for avoiding adverse events. *US Pharm.* 2014;39(11):34–6.
 6. Soubolsky A, Halpape K. The time is now for mental health care: evaluating the impact of a clinical pharmacist on an acute mental health unit. *Can J Hosp Pharm.* 2022;75(4):317–25. doi:10.4212/cjhp.3210
 7. Khartabil N, Haghighparast P, Al-Chokachi Z, Clemens E. The impact of pharmacists on medication safety in mental health: a narrative review. *J Am Coll Clin Pharm.* 2024;7(2):177–89. doi:10.1002/jac5.1900
 8. Rickles NM, Wertheimer AI, Smith MC. *Social and Behavioral Aspects of Pharmaceutical Care* (3rd edn.). Sudbury, MA: Jones & Bartlett Learning; 2010. 484 p.
 9. O'Reilly CL, Bell JS, Chen TF. Pharmacists' beliefs about treatments and outcomes of mental disorders: a mental health literacy survey. *Aust N Z J Psychiatry.* 2010;44(12):1089–96. doi:10.3109/00048674.2010.512864
 10. Shepherd N, Beveridge E, Parker C. Impact of a pharmacist in extended role on an acute mental health ward. *Prog Neurol Psychiatry.* 2022;26(3):27–30. doi:10.1002/pnp.758
 11. Ashcroft R, Mathers A, Gin A, Lam S, Donnelly C, Brown JB, et al. Pharmacists' role and experiences with delivering mental health care within team-based primary care settings during the COVID-19 pandemic. *Int J Pharm Pract.* 2024;32(2):156–63. doi:10.1093/ijpp/riad086
 12. El-Den S, Collins JC, Chen TF, O'Reilly CL. Pharmacists' roles in mental healthcare: past, present and future. *Pharm Pract (Granada).* 2021;19(3):2545. doi:10.18549/PharmPract.2021.3.2545
 13. Syrnok C, Glass BD. Pharmacist interventions in medication adherence in patients with mental health disorders: a scoping review. *Res Social Adm Pharm.* 2023;19(6):321–9. doi:10.1016/j.sapharm.2023.05.001
 14. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. *Basic Clin Pharmacol Toxicol.* 2007;100(1):4–22. doi:10.1111/j.1742-7843.2007.00017.x
 15. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med.* 2005;353(5):487–97. doi:10.1056/NEJMr050100
 16. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc.* 2011;86(4):304–14. doi:10.4065/mcp.2010.0575
 17. Klang SH, Ben-Amnon Y, Cohen Y, Barak Y. Community pharmacists' support improves antidepressant adherence in the community. *Int Clin Psychopharmacol.* 2015;30(6):316–9. doi:10.1097/YIC.0000000000000090
 18. McMillan SS, Kelly F, Hattingh HL, Fowler JL, Mihala G, Wheeler AJ. The impact of a person-centred community pharmacy mental health medication support service on consumer outcomes. *J Ment Health.* 2018;27(2):164–73. doi:10.1080/09638237.2017.1340618
 19. Bhat S, Kroehl ME, Trinkley KE, Chow Z, Heath LJ, Billups SJ, et al. Evaluation of a Clinical Pharmacist-Led Multidisciplinary Antidepressant Telemonitoring Service in the Primary Care Setting. *Popul Health Manag.* 2018;21(5):366–72. doi:10.1089/pop.2017.0144
 20. Bingham J, Silva-Almodóvar A, Lee H, Benson C, Michael R, Azurin CM, et al. The role of the pharmacist in mental health: An investigation of the impact of pharmacist-led interventions on psychotropic medication adherence in patients with diabetes. *J Am Pharm Assoc (2003).* 2020;60(4):58–63. doi:10.1016/j.japh.2020.01.009
 21. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. *J Clin Psychiatry.* 2010;71(6):669–81. doi:10.4088/JCP.10cs05959blu
 22. Vandenbroucke RE, Foulon V, De Vriese C, Van Boxem T, Simoens S. Evaluation of drug-drug interaction software in community and hospital pharmacy. *Eur J Clin Pharmacol.* 2012;68(5):547–55.
 23. Moini J, Ross M, editors. *Fundamentals of Pharmacology for Pharmacy Technicians*. 2nd ed. Boston, MA: CANGAGE Learning; 2016.
 24. Joel J. A Clinical Pharmacist-Led Study of Drug-Drug Interactions in patients with psychiatric disorders. *J Cell Mol Pharmacol.* 2022;6(4):130.

25. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. *Drugs*. 2009;69(13):1777–98. doi:10.2165/11317010-000000000-00000
26. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto. *Clin Pharmacol Ther*. 2004;76(5):428–40. doi:10.1016/j.clpt.2004.07.007
27. Wijesinghe R. A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. *Ment Health Clin*. 2016;6(1):21–7. doi:10.9740/mhc.2016.01.021
28. Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nat Rev Drug Discov*. 2012;11(2):141–68. doi:10.1038/nrd3628
29. Morrison RL, Stomski NJ, Whitely M. Strategies to support medication adherence in people with serious mental illness: a literature review. *Ment Health Prev*. 2018;10:31–41. doi:10.1016/j.mhp.2018.02.003
30. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. *World Psychiatry*. 2013;12(3):216–26. doi:10.1002/wps.20060
31. Moore CH, Powell BD, Kyle JA. The role of the community pharmacist in mental health. *US Pharm*. 2018;43(11):13–20.
32. Kremin Y, Lesyk L, Lesyk R, Levytska O, Khromovik B. Detailing the ten essential professional roles of the pharmacist to ensure the scope of professional functions. *Sci Pharm*. 2023;91(1):5. doi:10.3390/scipharm91010005
33. World Health Organization. The Role of the Pharmacist in the Health Care System – Preparing the Future Pharmacist: curricular development. Geneva: WHO; 1997. Report No.: WHO/PHARM/97/599. Available from: https://iris.who.int/bitstream/handle/10665/63817/WHO_PHARM_97_599.pdf [Accessed 01.04.2025].
34. International Pharmaceutical Federation (FIP). Development goals for pharmacy education and workforce. Available from: <https://www.fip.org/development-goals> [Accessed 15.05.2025].
35. National Institute of Mental Health [NIMH]. Mental Health Information. Available from: <https://www.nimh.nih.gov> [Accessed 25.01.2025].
36. Royal Pharmaceutical Society. Mental Health Roundtable Report. 2018.
37. Ministry of Health. Mental Health Policy 2004–2012. Available from: <https://www.mh.government.bg/upload/3453/politika-psihično-zdrave-2004-2012.pdf> [Accessed 25.03.2025].
38. Kamusheva M, Ignatova D, Golda A, Skowron A. The potential role of the pharmacist in supporting patients with depression – a literature-based point of view. *Integr Pharm Res Pract*. 2020;9:49–63. doi:10.2147/IPRP.S239672
39. Capoccia K, Boudreau D, Blough D, Ellsworth A, Clark D, Stevens N, et al. Randomised trial of pharmacist interventions to improve depression care and outcomes in primary care. *Am J Health Syst Pharm*. 2004;61(4):364–72. doi:10.1093/ajhp/61.4.364
40. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. *Dialogues Clin Neurosci*. 2008;10(4):409–18. doi:10.31887/DCNS.2008.10.4/kkelly
41. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. *Drug Healthc Patient Saf*. 2010;2:141–50. doi:10.2147/DHPS.S7634
42. Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. *Postgrad Med*. 2014;126(2):91–9. doi:10.3810/pgm.2014.03.2744
43. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. *Ment Health Clin*. 2016;6(4):191–6. doi:10.9740/mhc.2016.07.191
44. Chavez B, Kosirog E. Impact on an integrated psychiatric pharmacy service in a primary care clinic. *Ment Health Clin*. 2019;9(4):269–74. doi:10.9740/mhc.2019.07.269
45. Rieck M, Kim JA. Managing drug interactions with antidepressants. *US Pharm*. 2014;39(11):30–4.
46. Bingham J, Axon DR, Scovis N, Taylor AM. Evaluating the effectiveness of clinical pharmacy consultations on nutrition, physical activity, and sleep in improving patient-reported psychiatric outcomes for individuals with mental illnesses. *Pharmacy (Basel)*. 2018;7(1):2. doi:10.3390/pharmacy7010002

47. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. *BMJ*. 2005;330(7488):396. doi:10.1136/bmj.330.7488.396
48. National Institute on Drug Abuse [NIDA]. Medications for substance use disorders. Available from: <https://nida.nih.gov> [Accessed 25.03.2025].
49. Cochran G, Gordon AJ, Lo-Ciganic W. Prescription opioid misuse: pharmacists' role in preventing abuse. *J Am Pharm Assoc*. 2017;57(2):S67–S72.e2. doi:10.1016/j.japh.2017.01.010
50. American Society of Health-System Pharmacists (ASHP). ASHP Guidelines on the pharmacist's role in substance use prevention and education. *Am J Health Syst Pharm*. 2019;76(5):356–67. doi:10.1093/ajhp/zxy080
51. Lindson N, Richards-Doran D, Heath L, Hartmann-Boyce J. Motivational interviewing for substance use. *Cochrane Database Syst Rev*. 2023;(12):1–219. doi:10.1002/14651858.CD008063.pub3
52. International Pharmaceutical Federation (FIP). Pharmacy's role in harm reduction. Available from: <https://www.fip.org/file/4325> [Accessed 25.02.2025].
53. Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis — Buprenorphine myths and realities. *N Engl J Med*. 2018;379(1):1–4. doi:10.1056/NEJMp1802741
54. Winstanley EL, Clark AN. Engaging pharmacists to address the opioid crisis: a review of programs. *Subst Abus*. 2018;39(2):211–5.
55. Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. *Pharmacotherapy*. 2003;23(12):1634–44. doi:10.1592/phco.23.15.1634.63502
56. Ministry of Health. National Strategy for the Development of Clinical Pharmacy in Hospital Care. Available from: <https://old.mh.government.bg/bg/politiki/strategii-i-kontseptsii/strategii/> [Accessed 15.05.2025].
57. Eaves S, Gonzalvo J, Hamm JA, Williams G, Ott C. The evolving role of the pharmacist for individuals with serious mental illness. *J Am Pharm Assoc*. 2020;60(5):S11–S4. doi:10.1016/j.japh.2020.04.017
58. Farag M, Chalmers L, Hoti K, Hughes J. The role of the clinical pharmacist in mental health hospital-in-the-home: a scoping review. *Res Social Adm Pharm*. 2022;18(10):3724–35. doi:10.1016/j.sapharm.2022.04.004
59. Getov I, Kostov E, Lebanova H, Grigorov E. Clinical pharmacy – essence, progress and challenges in practice. *Med Pregl*. 2013;49(3):30–7.
60. Medical University of Plovdiv. Curriculum for the specialization “Pharmacist Assistant.” Available from: https://mu-plovdiv.bg/wp-content/uploads/2020/10/uchebni_programi_spetsialnost_spetsialnost_pomoshtnik_farmacevt.pdf#page=363 [Accessed 01.03.2025].